New Delhi: Days after the World Health Organisation (WHO) put a pause on clinical trials of anti-malaria drug hydroxychloroquine for COVID-19 treatment over safety concerns, the United Nations agency on Wednesday said that trials can resume.Also Read - Disregards Common Sense, Defies Science: China on WHO's Plan For 2nd Phase of Probe Into Covid Origins
Also Read - Prevalence of Delta Variant Among Specimens Sequenced Over Past 4 weeks Exceeded 75%: WHO
“On the basis of the available mortality data… the executive group will communicate with the principal investigators in the trial about resuming the hydroxychloroquine arm,” AFP quoted WHO chief Tedros Adhanom Ghebreyesus as saying. Also Read - Premature to Rule Out Potential Link Between Covid & Lab Leak: WHO Chief
Hydroxychloroquine is a common anti-malaria drug which is considered effective to slow infections from the Covid-19, SARS-CoV-2 etc.